Design, synthesis, and biological evaluation of bone-targeted proteasome inhibitors for multiple myeloma

Joseph K. Agyin, Bindu Santhamma, Sudipa S. Roy

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Multiple myeloma (MM) is an incurable neoplasm characterized by devastating and progressive bone destruction. Standard chemotherapeutic agents have not been effective at significantly prolonging the survival of MM patients and these agents are typically associated with often severe, dose-limiting side effects. There is great need for methods to target the delivery of novel, effective cytotoxic agents specifically to bone, where myeloma cells reside. We have synthesized and evaluated the effects of the bone-targeted proteasome inhibitors PS-341-BP-1, PS-341-BP-2 and MG-262-BP on cell proliferation using the mouse 5TGM1 and human RPMI 8226 cell lines in vitro. The compounds exhibit strong cytotoxicity on MM cell lines and reduce the number of viable cells in a dose dependent manner.

Original languageEnglish (US)
Pages (from-to)6455-6458
Number of pages4
JournalBioorganic and Medicinal Chemistry Letters
Volume23
Issue number23
DOIs
StatePublished - Dec 1 2013

Fingerprint

Proteasome Inhibitors
Multiple Myeloma
Bone
Bone and Bones
Cells
Cell Line
Cytotoxins
Cell proliferation
Proxy
Cytotoxicity
Cell Count
Cell Proliferation
Survival
Neoplasms
Bortezomib

Keywords

  • Bisphosphonate conjugate
  • Bone-targeted
  • Boronic acid
  • Multiple myeloma
  • Proteasome inhibitor

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Drug Discovery
  • Organic Chemistry
  • Molecular Medicine
  • Molecular Biology
  • Clinical Biochemistry
  • Biochemistry

Cite this

Design, synthesis, and biological evaluation of bone-targeted proteasome inhibitors for multiple myeloma. / Agyin, Joseph K.; Santhamma, Bindu; Roy, Sudipa S.

In: Bioorganic and Medicinal Chemistry Letters, Vol. 23, No. 23, 01.12.2013, p. 6455-6458.

Research output: Contribution to journalArticle

Agyin, Joseph K. ; Santhamma, Bindu ; Roy, Sudipa S. / Design, synthesis, and biological evaluation of bone-targeted proteasome inhibitors for multiple myeloma. In: Bioorganic and Medicinal Chemistry Letters. 2013 ; Vol. 23, No. 23. pp. 6455-6458.
@article{723dd7cf24354f2ab0fda3ceab7a85fe,
title = "Design, synthesis, and biological evaluation of bone-targeted proteasome inhibitors for multiple myeloma",
abstract = "Multiple myeloma (MM) is an incurable neoplasm characterized by devastating and progressive bone destruction. Standard chemotherapeutic agents have not been effective at significantly prolonging the survival of MM patients and these agents are typically associated with often severe, dose-limiting side effects. There is great need for methods to target the delivery of novel, effective cytotoxic agents specifically to bone, where myeloma cells reside. We have synthesized and evaluated the effects of the bone-targeted proteasome inhibitors PS-341-BP-1, PS-341-BP-2 and MG-262-BP on cell proliferation using the mouse 5TGM1 and human RPMI 8226 cell lines in vitro. The compounds exhibit strong cytotoxicity on MM cell lines and reduce the number of viable cells in a dose dependent manner.",
keywords = "Bisphosphonate conjugate, Bone-targeted, Boronic acid, Multiple myeloma, Proteasome inhibitor",
author = "Agyin, {Joseph K.} and Bindu Santhamma and Roy, {Sudipa S.}",
year = "2013",
month = "12",
day = "1",
doi = "10.1016/j.bmcl.2013.09.043",
language = "English (US)",
volume = "23",
pages = "6455--6458",
journal = "Bioorganic and Medicinal Chemistry Letters",
issn = "0960-894X",
publisher = "Elsevier Limited",
number = "23",

}

TY - JOUR

T1 - Design, synthesis, and biological evaluation of bone-targeted proteasome inhibitors for multiple myeloma

AU - Agyin, Joseph K.

AU - Santhamma, Bindu

AU - Roy, Sudipa S.

PY - 2013/12/1

Y1 - 2013/12/1

N2 - Multiple myeloma (MM) is an incurable neoplasm characterized by devastating and progressive bone destruction. Standard chemotherapeutic agents have not been effective at significantly prolonging the survival of MM patients and these agents are typically associated with often severe, dose-limiting side effects. There is great need for methods to target the delivery of novel, effective cytotoxic agents specifically to bone, where myeloma cells reside. We have synthesized and evaluated the effects of the bone-targeted proteasome inhibitors PS-341-BP-1, PS-341-BP-2 and MG-262-BP on cell proliferation using the mouse 5TGM1 and human RPMI 8226 cell lines in vitro. The compounds exhibit strong cytotoxicity on MM cell lines and reduce the number of viable cells in a dose dependent manner.

AB - Multiple myeloma (MM) is an incurable neoplasm characterized by devastating and progressive bone destruction. Standard chemotherapeutic agents have not been effective at significantly prolonging the survival of MM patients and these agents are typically associated with often severe, dose-limiting side effects. There is great need for methods to target the delivery of novel, effective cytotoxic agents specifically to bone, where myeloma cells reside. We have synthesized and evaluated the effects of the bone-targeted proteasome inhibitors PS-341-BP-1, PS-341-BP-2 and MG-262-BP on cell proliferation using the mouse 5TGM1 and human RPMI 8226 cell lines in vitro. The compounds exhibit strong cytotoxicity on MM cell lines and reduce the number of viable cells in a dose dependent manner.

KW - Bisphosphonate conjugate

KW - Bone-targeted

KW - Boronic acid

KW - Multiple myeloma

KW - Proteasome inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84886951236&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886951236&partnerID=8YFLogxK

U2 - 10.1016/j.bmcl.2013.09.043

DO - 10.1016/j.bmcl.2013.09.043

M3 - Article

C2 - 24119559

AN - SCOPUS:84886951236

VL - 23

SP - 6455

EP - 6458

JO - Bioorganic and Medicinal Chemistry Letters

JF - Bioorganic and Medicinal Chemistry Letters

SN - 0960-894X

IS - 23

ER -